Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Yoshiicerus persimilis

ABSTRACT: Yoshiicerus persimilis Genome sequencing and assembly

PROVIDER: PRJNA630033 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR13480400_1.fastq.gz	Fastqsanger.gz
	SRR13480400_2.fastq.gz	Fastqsanger.gz
	SRR13480401_subreads.fastq.gz	Fastqsanger.gz
	SRR13480398.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Phytoseiulus persimilis

Project description:Phytoseiulus persimilis Genome sequencing and assembly

| PRJNA1128535 | ENA

Artemia persimilis

Project description:Artemia persimilis complete mitochondrial genome sequencing and assembly

| PRJNA749897 | ENA

Phytoseiulus persimilis

Project description:Phytoseiulus persimilis overview

| PRJNA947280 | ENA

Drosophila persimilis strain:M40

Project description:Drosophila persimilis strain:M40 Genome sequencing and assembly

| PRJNA753501 | ENA

Drosophila persimilis

Project description:Whole genome shotgun (WGS) sequencing of Drosophila persimilis

| PRJNA12705 | ENA

Phytoseiulus persimilis

Project description:Phytoseiulus persimilis Raw sequence reads

| PRJNA893882 | ENA

Phytoseiulus persimilis

Project description:Phytoseiulus persimilis Transcriptome or Gene expression

| PRJNA893866 | ENA

Drosophila persimilis

Project description:The fruit fly Drosophila persimilis is a member of the obscura group of the subgenus Sophophora

| PRJNA12695 | ENA

Project description:Phytoseiulus persimilis sequencing

| PRJNA784037 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data